MedTrace Logo

Dose Response of a Tubule Occlusion Agent

NCT01075256 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2013-06-03

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy of two different concentrations of a tubule occlusion agent - calcium sodium phosphosilicate in treatment of dentine hypersensitivity

Conditions

  • Dentine Hypersensitivity
  • Dental Pain

Interventions

DEVICE

5% calcium sodium phosphosilicate toothpaste

Low concentration calcium sodium phosphosilicate tubule occlusion agent

DEVICE

7.5% calcium sodium phosphosilicate toothpaste

High concentration calcium sodium phosphosilicate tubule occlusion agent

DEVICE

Placebo toothpaste

Placebo toothpaste

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01075256 on ClinicalTrials.gov